MARATTO

article · Ain Shams Medical Journal

A STUDY OF SERUM HEPCIDIN LEVEL IN RELATION TO CLINICAL ACTIVITY INDICES AND COMPLETE BLOOD PICTURE PARAMETERS IN RHEUMATOID ARTHRITIS PATIENTS

2024Open accessAin Shams University

Abstract

Background: Rheumatoid arthritis (RA) is a chronic auto-immune-mediated inflammatory arthritis that affects around one percent of the human population. One of the common comorbidities encountered in rheumatoid patients is anemia. Hepcidin being one of the acute-phase reactant proteins, it acts as a homeostatic regulator of iron metabolism and as an inflammatory mediator as well. Aim of The Work: This study aims to evaluate the value of measuring serum hepcidin levels in patients with rheumatoid arthritis and its relationship with clinical disease activity and blood parameters.Methods: fifty RA patients underwent full medical assessment with the evaluation of DAS-28 score, laboratory tests including CBC, ESR, rheumatoid factor and anti-CCP, serum ferritin and serum iron, and serum hepcidin level.Results: Our results showed that there was a statistically significant correlation between inflammatory markers and serum hepcidin level, as well as a positive correlation between the degree of disease activity measured by DAS 28 score with serum hepcidin level. Conclusion: We concluded from our study that serum hepcidin can be used to assess the disease activity in rheumatoid arthritis patients and rheumatoid-related anemias as well.

Research topics

  • Erythropoietin and Anemia Treatment
  • Diverse Scientific Research Studies
  • Iron Metabolism and Disorders

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/asmj.2024.268217.1220

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.